PROTAC HK2 Degrader-1

PROTAC HK2 Degrader-1

• CAS Number: 3033812-84-6
• UNSPSC Description: PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research[1].
• Target Antigen: Hexokinase; PROTACs
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease;PROTAC
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/protac-hk2-degrader-1.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(N1)CCC(N(C(C2=C3C=CC=C2NCCCCNC(C4=NN(C5=C4C=CC=C5)CC6=C(C=C(C=C6)Cl)Cl)=O)=O)C3=O)C1=O
• Molecular Weight: 647.51
• References & Citations: [1]Sang R, et al. Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy. J Med Chem. 2023 Jun 27.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported